Status:
COMPLETED
Guideline-Directed Medical Therapy in Patients After Implantation of Implantable Cardioverter Defibrillators to Improve Long-Term Outcomes
Lead Sponsor:
Ratika Parkash
Collaborating Sponsors:
Nova Scotia Health Authority
Conditions:
Heart Failure
ICD
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Guideline-directed medical therapy (GDMT) and the mortality benefit it provides in the heart failure with reduced ejection fraction (HFrEF) population are well-established by multiple professional soc...
Detailed Description
Guideline-directed medical therapy (GDMT) and the mortality benefit it provides in the heart failure with reduced ejection fraction (HFrEF) population are well-established by multiple professional soc...
Eligibility Criteria
Inclusion
- \- patients who underwent ICD or CRT (pacemaker or defibrillator) implantation therapy at the QEII Health Sciences Centre between 2002 and 2019 and had a left ventricular ejection fraction ≤ 35% at the time of the initial implantation.
Exclusion
- unable to provide informed consent, has a life expectancy of less than one year, dementia, cirrhosis, or metastatic malignancy.
- Patients who underwent primary prevention ICD implantation for arrhythmogenic right ventricular cardiomyopathy (ARVC), ion channelopathies, hypertrophic cardiomyopathy, or infiltrative cardiomyopathy will be excluded from this analysis.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04505007
Start Date
June 1 2021
End Date
August 31 2024
Last Update
November 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada, B3H 3A7